Serum immune biomarkers in irritable bowel syndrome.

S. Seyedmirzaee,M. Hayatbakhsh,Bizhan Ahmadi,Nadieh Baniasadi,Afshin Mohammad Bagheri Rafsanjani,A. Nikpoor,M. Mohammadi

DOI: https://doi.org/10.1016/j.clinre.2015.12.013

IF: 3.189

2016-11-01

Clinics and Research in Hepatology and Gastroenterology

Abstract:

What problem does this paper attempt to address?

B Cells in Atherosclerosis: Mechanisms and Potential Clinical Applications

Tanyaporn Pattarabanjird,Cynthia Li,Coleen McNamara

DOI: https://doi.org/10.1016/j.jacbts.2021.01.006

2021-06-28

Abstract:Because atherosclerotic cardiovascular disease is a leading cause of death worldwide, understanding inflammatory processes underpinning its pathology is critical. B cells have been implicated as a key immune cell type in regulating atherosclerosis. B-cell effects, mediated by antibodies and cytokines, are subset specific. In this review, we focus on elaborating mechanisms underlying subtype-specific roles of B cells in atherosclerosis and discuss available human data implicating B cells in atherosclerosis. We further discuss potential B cell-linked therapeutic approaches, including immunization and B cell-targeted biologics. Given recent evidence strongly supporting a role for B cells in human atherosclerosis and the expansion of immunomodulatory agents that affect B-cell biology in clinical use and clinical trials for other disorders, it is important that the cardiovascular field be cognizant of potential beneficial or untoward effects of modulating B-cell activity on atherosclerosis.
Functional Role of B Cells in Atherosclerosis

Shelby D.,Marion Mussbacher,Elena V. Galkina,Shelby D. Ma

DOI: https://doi.org/10.3390/cells10020270

IF: 6

2021-01-29

Cells

Abstract:Atherosclerosis is a lipid-driven inflammatory disease of blood vessels, and both innate and adaptive immune responses are involved in its development. The impact of B cells on atherosclerosis has been demonstrated in numerous studies and B cells have been found in close proximity to atherosclerotic plaques in humans and mice. B cells exert both atheroprotective and pro-atherogenic functions, which have been associated with their B cell subset attribution. While B1 cells and marginal zone B cells are considered to protect against atherosclerosis, follicular B cells and innate response activator B cells have been shown to promote atherosclerosis. In this review, we shed light on the role of B cells from a different, functional perspective and focus on the three major B cell functions: antibody production, antigen presentation/T cell interaction, and the release of cytokines. All of these functions have the potential to affect atherosclerosis by multiple ways and are dependent on the cellular milieu and the activation status of the B cell. Moreover, we discuss B cell receptor signaling and the mechanism of B cell activation under atherosclerosis-prone conditions. By summarizing current knowledge of B cells in and beyond atherosclerosis, we are pointing out open questions and enabling new perspectives.

cell biology
Beyond Macrophages and T Cells: B Cells and Immunoglobulins Determine the Fate of the Atherosclerotic Plaque

Harald Mangge,Florian Prüller,Wolfgang Schnedl,Wilfried Renner,Gunter Almer

DOI: https://doi.org/10.3390/ijms21114082

IF: 5.6

2020-06-08

International Journal of Molecular Sciences

Abstract:Atherosclerosis (AS) leading to myocardial infarction and stroke remains worldwide the main cause for mortality. Vulnerable atherosclerotic plaques are responsible for these life-threatening clinical endpoints. Atherosclerosis is a chronic, complex, inflammatory disease with interactions between metabolic dysfunction, dyslipidemia, disturbed microbiome, infectious triggers, vascular, and immune cells. Undoubtedly, the immune response is a most important piece of the pathological puzzle in AS. Although macrophages and T cells have been the focus of research in recent years, B cells producing antibodies and regulating T and natural killer (NKT) cell activation are more important than formerly thought. New results show that the B cells exert a prominent role with atherogenic and protective facets mediated by distinct B cell subsets and different immunoglobulin effects. These new insights come, amongst others, from observations of the effects of innovative B cell targeted therapies in autoimmune diseases like systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). These diseases associate with AS, and the beneficial side effects of B cell subset depleting (modifying) therapies on atherosclerotic concomitant disease, have been observed. Moreover, the CANTOS study (NCT01327846) showed impressive results of immune-mediated inflammation as a new promising target of action for the fight against atherosclerotic endpoints. This review will reflect the putative role of B cells in AS in an attempt to connect observations from animal models with the small spectrum of the thus far available human data. We will also discuss the clinical therapeutic potency of B cell modulations on the process of AS.

biochemistry & molecular biology,chemistry, multidisciplinary
Atherosclerosis antigens as targets for immunotherapy

Irene Raposo-Gutiérrez,Ana Rodríguez-Ronchel,Almudena R Ramiro

DOI: https://doi.org/10.1038/s44161-023-00376-x

Abstract:Atherosclerosis is a chronic inflammatory disease of the arteries that can lead to thrombosis, infarction and stroke, underlying the first cause of mortality worldwide. Adaptive immunity plays critical roles in atherosclerosis, and numerous studies have ascribed both atheroprotective and atherogenic functions to specific subsets of T and B cells. However, less is known on how antigen specificity determines the protective or adverse outcome of such adaptive responses. Understanding antigen triggers in atherosclerosis is crucial to delve deeper into mechanisms of disease initiation and progression and to implement specific immunotherapeutic approaches, including vaccination strategies. Here we review the role of adaptive immunity in atherosclerosis and the insights that single-cell technology has provided into the function of distinct immune cell subsets. We outline the most relevant atherosclerosis antigens and antibodies reported to date and examine their immunotherapeutic potential. Finally, we review the most promising vaccination-based clinical trials targeting the adaptive immune system.
B cells and atherosclerosis: A HIV perspective

Laventa M. Obare,Rachel H. Bonami,Amanda C. Doran,Celestine N. Wanjalla

DOI: https://doi.org/10.1002/jcp.31270

2024-04-25

Journal of Cellular Physiology

Abstract:Atherosclerosis remains a leading cause of cardiovascular disease (CVD) globally, with the complex interplay of inflammation and lipid metabolism at its core. Recent evidence suggests a role of B cells in the pathogenesis of atherosclerosis; however, this relationship remains poorly understood, particularly in the context of HIV. We review the multifaceted functions of B cells in atherosclerosis, with a specific focus on HIV. Unique to atherosclerosis is the pivotal role of natural antibodies, particularly those targeting oxidized epitopes abundant in modified lipoproteins and cellular debris. B cells can exert control over cellular immune responses within atherosclerotic arteries through antigen presentation, chemokine production, cytokine production, and cell–cell interactions, actively participating in local and systemic immune responses. We explore how HIV, characterized by chronic immune activation and dysregulation, influences B cells in the context of atherosclerosis, potentially exacerbating CVD risk in persons with HIV. By examining the proatherogenic and antiatherogenic properties of B cells, we aim to deepen our understanding of how B cells influence atherosclerotic plaque development, especially within the framework of HIV. This research provides a foundation for novel B cell‐targeted interventions, with the potential to mitigate inflammation‐driven cardiovascular events, offering new perspectives on CVD risk management in PLWH.

cell biology,physiology
Antibodies in action: the role of humoral immunity in the fight against atherosclerosis

Joshua A. Taylor,Mark A. Hutchinson,Patricia J. Gearhart,Robert W. Maul

DOI: https://doi.org/10.1186/s12979-022-00316-6

2022-12-03

Abstract:The sequestering of oxidation-modified low-density lipoprotein by macrophages results in the accumulation of fatty deposits within the walls of arteries. Necrosis of these cells causes a release of intercellular epitopes and the activation of the adaptive immune system, which we predict leads to robust autoantibody production. T cells produce cytokines that act in the plaque environment and further stimulate B cell antibody production. B cells in atherosclerosis meanwhile have a mixed role based on subclass. The current model is that B-1 cells produce protective IgM antibodies in response to oxidation-specific epitopes that work to control plaque formation, while follicular B-2 cells produce class-switched antibodies (IgG, IgA, and IgE) which exacerbate the disease. Over the course of this review, we discuss further the validation of these protective antibodies while evaluating the current dogma regarding class-switched antibodies in atherosclerosis. There are several contradictory findings regarding the involvement of class-switched antibodies in the disease. We hypothesize that this is due to antigen-specificity, and not simply isotype, being important, and that a closer evaluation of these antibodies' targets should be conducted. We propose that specific antibodies may have therapeutical potential in preventing and controlling plaque development within a clinical setting.

immunology,geriatrics & gerontology,gerontology
T Cells in Atherosclerosis: Key Players in the Pathogenesis of Vascular Disease

Hannah Hinkley,Daniel A. Counts,Elizabeth VonCanon,Michael Lacy

DOI: https://doi.org/10.3390/cells12172152

IF: 6

2023-08-27

Cells

Abstract:Atherosclerosis is a chronic inflammatory disease characterized by the accumulation of lipid-rich plaques within arterial walls. T cells play a pivotal role in the pathogenesis of atherosclerosis in which they help orchestrate immune responses and contribute to plaque development and instability. Here, we discuss the recognition of atherosclerosis-related antigens that may trigger T cell activation together with additional signaling from co-stimulatory molecules and lesional cytokines. Although few studies have indicated candidates for the antigen specificity of T cells in atherosclerosis, further research is needed. Furthermore, we describe the pro-atherogenic and atheroprotective roles of diverse subsets of T cells such as CD4+ helper, CD8+ cytotoxic, invariant natural killer, and γδ T cells. To classify and quantify T cell subsets in atherosclerosis, we summarize current methods to analyze cellular heterogeneity including single cell RNA sequencing and T cell receptor (TCR) sequencing. Further insights into T cell biology will help shed light on the immunopathology of atherosclerosis, inform potential therapeutic interventions, and pave the way for precision medicine approaches in combating cardiovascular disease.

cell biology
Atherosclerosis: Beyond the lipid storage hypothesis. The role of autoimmunity

Ilir I. Cinoku,Clio P. Mavragani,Haralampos M. Moutsopoulos

DOI: https://doi.org/10.1111/eci.13195

2020-01-18

European Journal of Clinical Investigation

Abstract:Atherosclerosis has long been considered as a lipid storage disease. Recent data suggest that autoimmune mechanisms seem to be involved in the pathophysiology of atherosclerosis. The presence of activated endothelial vascular cells, neutrophils, macrophages, T‐ and to a lesser extent B‐cells in atherosclerotic plaques, together with the proinflammatory cytokine burden suggest mobilization of both innate and adaptive immune pathways in atherosclerosis pathobiology. The development of antibodies to oxidized low‐density lipoprotein (ox‐LDL), the experimental induction of atherosclerosis either via the transfer of T‐cells or immunization with autoantigens such as β2 glycoprotein Ι (β2‐GPI) and heat shock proteins (HSP) further support the autoimmune nature of atherosclerosis. However, classical immunosuppressive and immune‐modulatory drugs, successfully used in the therapy of autoimmune rheumatic diseases have shown limited benefits so far in the treatment of atherosclerosis.

medicine, general & internal, research & experimental
Tipping the Scale: Atheroprotective IgM-Producing B Cells in Atherosclerosis

Brett Patrick Ransegnola,Tanyaporn Pattarabanjird,Coleen A. McNamara

DOI: https://doi.org/10.1161/atvbaha.124.319847

2024-07-20

Arteriosclerosis Thrombosis and Vascular Biology

Abstract:Arteriosclerosis, Thrombosis, and Vascular Biology, Ahead of Print. Atherosclerosis is a chronic inflammatory disease whose progression is fueled by proinflammatory moieties and limited by anti-inflammatory mediators. Whereas oxidative damage and the generation of oxidation-specific epitopes that act as damage-associated molecular patterns are highly inflammatory, IgM antibodies produced by B-1 and marginal zone B cells counteract unrestricted inflammation by neutralizing and encouraging clearance of these proinflammatory signals. In this review, we focus on describing the identities of IgM-producing B cells in both mice and humans, elaborating the mechanisms underlying IgM production, and discussing the potential strategies to augment the production of atheroprotective IgM. In addition, we will discuss promising therapeutic interventions in humans to help tip the scale toward augmentation of IgM production and to provide atheroprotection.

peripheral vascular disease,hematology
ApoB-Specific CD4+ T Cells in Mouse and Human Atherosclerosis

Timoteo Marchini,Sophie Hansen,Dennis Wolf

DOI: https://doi.org/10.3390/cells10020446

IF: 6

2021-02-19

Cells

Abstract:Atherosclerosis is a chronic inflammatory condition of the arterial wall that leads to the formation of vessel-occluding plaques within the subintimal space of middle-sized and larger arteries. While traditionally understood as a myeloid-driven lipid-storage disease, growing evidence suggests that the accumulation of low-density lipoprotein cholesterol (LDL-C) ignites an autoimmune response with CD4+ T-helper (TH) cells that recognize self-peptides from Apolipoprotein B (ApoB), the core protein of LDL-C. These autoreactive CD4+ T cells home to the atherosclerotic plaque, clonally expand, instruct other cells in the plaque, and induce clinical plaque instability. Recent developments in detecting antigen-specific cells at the single cell level have demonstrated that ApoB-reactive CD4+ T cells exist in humans and mice. Their phenotypes and functions deviate from classical immunological concepts of distinct and terminally differentiated TH immunity. Instead, ApoB-specific CD4+ T cells have a highly plastic phenotype, can acquire several, partially opposing and mixed transcriptional programs simultaneously, and transit from one TH subset into another over time. In this review, we highlight adaptive immune mechanisms in atherosclerosis with a focus on CD4+ T cells, introduce novel technologies to detect ApoB-specific CD4+ T cells at the single cell level, and discuss the potential impact of ApoB-driven autoimmunity in atherosclerosis.

cell biology
Targeting immune cell recruitment in atherosclerosis

Yvonne Döring,Emiel P. C. van der Vorst,Christian Weber

DOI: https://doi.org/10.1038/s41569-024-01023-z

IF: 49.421

2024-04-27

Nature Reviews Cardiology

Abstract:Atherosclerosis is the primary underlying cause of myocardial infarction and stroke. Atherosclerotic cardiovascular disease is characterized by a chronic inflammatory reaction in medium-to-large-sized arteries, with its onset and perpetuation driven by leukocytes infiltrating the subendothelial space. Activation of endothelial cells triggered by hyperlipidaemia and lipoprotein retention in the arterial intima initiates the accumulation of pro-inflammatory leukocytes in the arterial wall, fostering the progression of atherosclerosis. This inflammatory response is coordinated by an array of soluble mediators, namely cytokines and chemokines, that amplify inflammation both locally and systemically and are complemented by tissue-specific molecules that regulate the homing, adhesion and transmigration of leukocytes. Despite abundant evidence from mouse models, only a few therapies targeting leukocytes in atherosclerosis have been assessed in humans. The major challenges for the clinical translation of these therapies include the lack of tissue specificity and insufficient selectivity of inhibition strategies. In this Review, we discuss the latest research on receptor–ligand pairs and interactors that regulate leukocyte influx into the inflamed artery wall, primarily focusing on studies that used pharmacological interventions. We also discuss mechanisms that promote the resolution of inflammation and highlight how major findings from these research areas hold promise as potential therapeutic strategies for atherosclerotic cardiovascular disease.

cardiac & cardiovascular systems
Abstract 21: B-1b Cells Secrete Atheroprotective IgM and Attenuate Atherosclerosis

Sam Morris-Rosenfeld,Heather M Perry,Prasad Srikakulapu,Chantel McSkimming,Ayelet Gonen,Thomas A Prohaska,Sotirios Tsimikas,Joseph L Witztum,Timothy P Bender,Angela Taylor,Coleen A McNamara

DOI: https://doi.org/10.1161/atvb.35.suppl_1.21

2015-05-01

Abstract:Rationale: B cells contribute to atherosclerosis through subset specific mechanisms. Whereas some controversy exists about the role of B-2 B cells, B-1a B cells are atheroprotective. The function of B-1b B cells, a unique subset of B-1 cells that can produce T cell-independent (TI) memory, has not been studied within the context of atherosclerosis. Objective: To determine whether B-1b cells produce atheroprotective IgM antibodies and function to protect against diet induced atherosclerosis. Methods and Results: We demonstrate that B-1b cells are sufficient to produce IgM antibodies against oxidation specific epitopes (OSE) on LDL in vitro in response to activating stimulation. Additionally, we demonstrate that B-1b cells provide direct atheroprotection after adoptive transfer into B and T cell deficient (Rag1-/-Apoe-/-) hosts. To support these findings, we utilize a B cell specific Id3 knockout mouse model (Id3BKO), which develops increased numbers of B-1b cells systemically, to demonstrate that these mice develop attenuated atherosclerosis and increased OSE IgM antibodies compared to wild-type controls (Id3WT) after being fed a Western diet for 16 weeks. Finally, we report that the presence of a functionally relevant homozygous SNP in ID3 in humans associates with increased proportion of circulating B-1 cells and anti-MDA-LDL IgM and that the percentage of circulating B-1 cells is directly associated with the amount of anti-MDA-LDL IgM suggesting clinical relevance. Conclusions: These results provide novel evidence that B-1b B cells produce atheroprotective OSE IgM antibodies and protect against atherosclerosis in mice, and suggest that similar mechanisms may occur in humans.
Single-cell profiling of CD11c+ B cells in atherosclerosis

Tanyaporn Pattarabanjird,Prasad Srikakulapu,Brett Ransegnola,Melissa A. Marshall,Yanal Ghosheh,Rishab Gulati,Chistopher Durant,Fabrizio Drago,Angela M. Taylor,Klaus Ley,Coleen A. McNamara

DOI: https://doi.org/10.3389/fimmu.2023.1296668

IF: 7.3

2024-01-08

Frontiers in Immunology

Abstract:Circulating CD11c+ B cells, a novel subset of activated B cells, have been linked to autoimmunity and shown to expand with age. Atherosclerosis is an age-associated disease that involves innate and adaptive immune responses to modified self-antigens. Yet, the expression of CD11c on specific B-cell subtypes and its link to atherosclerosis are poorly understood. In this study, we characterized the frequency of CD11c+ B cells in tissues in mice with aging. We observed an age-associated increase in CD11c+ B cells in the spleen and bone marrow of ApoE −/− mice, and this was associated with an increase in aortic plaque. In addition, we also utilized single-cell multi-omics profiling of 60 human subjects undergoing advanced imaging for coronary artery disease (CAD) to subtype CD11c+ B cells and determine their frequency in subjects with high and low severity of CAD. Using unsupervised clustering, we identified four distinct clusters of CD11c+ B cells, which include CD27 and IgD double negative 2 (DN2), age-associated (ABC), CD11c+ unswitched memory (USWM), and activated Naïve (aNav) B cells. We observed an increase in the frequency of both ABC B cells and DN2 B cells in patients with high CAD severity. Pathway analysis further demonstrated augmentation of autophagy, IFNg signaling, and TLR signaling in DN2 cells in high-severity CAD patients. On the other hand, an increase in the negative regulator of BCR signaling through CD72 was found in ABC cells in low-severity CAD patients. Through investigating scRNAseq of atheroma, these DN2 cells were also found to infiltrate human coronary atheroma.

immunology
Inhibitory effects of apple polyphenol on induced histamine release from RBL-2H3 cells and rat mast cells.

Tomomasa Kanda,Hiroshi Akiyama,Akio Yanagida,Masayuki Tanabe,Yukihiro Goda,Masatake Toyoda,Reiko Teshima,Yukio Saito

DOI: https://doi.org/10.1271/BBB.62.1284

1998-07-23

Abstract:The anti-allergic activities of polyphenol fractions extracted from immature fruits of apple (Rosaceae, Malus sp.) were evaluated by in vitro assays. A crude apple polyphenol (CAP) fraction, which had been obtained from the juice of immature apples by reverse-phase column chromatography, was further purified by LH-20 column chromatography to obtain an apple condensed tannin (ACT) fraction consisting of linear oligomeric epicatechins from the dimer to pentadecamer. ACT strongly inhibited the release of histamine from rat basophilic leukemia (RBL-2H3) cells stimulated by the antigen-stimulation and from rat peritoneal mast cells stimulated by compound 48/80. The IC50 values for histamine release were 30 micrograms/ml and 25 micrograms/ml, respectively. ACT also inhibited hyaluronidase activity and the increase in intracellular free calcium concentration in RBL-2H3 cells stimulated with the antigen. These results suggest that ACT affected early signal transduction including the calcium influx.
The cellular biology of atherosclerosis with atherosclerotic lesion classification and biomarkers

Leta Melaku,Addisu Dabi

DOI: https://doi.org/10.1186/s42269-021-00685-w

2021-12-01

Bulletin of the National Research Centre

Abstract:Abstract Background Atherosclerosis is a chronic lipid-driven inflammatory disease with infiltration of low-density lipoprotein and is considered as the pivotal step in plaque formation. The aim of the review is to get into the fine details of pathophysiologic mechanisms responsible for atherosclerosis with atherosclerotic lesion classification. It also provides a summary of current biomarkers other than the traditional risk factors so that new treatment modalities can emerge and reduce the morbidity and mortality associated with atherosclerosis. Main body In the classification of atherosclerosis made by American Heart Association (AHA), AHA Type I lesion is the earliest vascular change described microscopically. AHA Type II lesion is primarily composed of abundant macrophages. AHA Type III lesion is the earliest of progressive lesions, while AHA Type IV lesion consists of an acellular necrotic core. Various biomarkers are implicated in different stages of the pathophysiological mechanism of plaque formation and evolution. C Reactive Protein plays a direct role in promoting the inflammatory component of atherosclerosis. Fibrinogen was demonstrated to be elevated among patients with acute thrombosis. Higher leukocyte count is associated with a greater cardiovascular risk. Cytokines have been implicated in atheroma formation and complications. High rates of protease activated receptor expression are also induced by interleukin-6 secretion in atherosclerotic lesions and areas of vascular tissue injury. Cluster of differentiation 40 receptor and its ligand have been also detected in atherosclerotic plaques. Osteopontin, acidic phosphoprotein, and osteoprotegerin have emerged as novel markers of atherosclerotic plaque composition. There are also overproductions of matrix metalloproteinases in the rupture-prone regions and promote lipid-necrotic core formation in the atherosclerotic plaque. Myeloperoxidase has been proposed as a marker of plaque instability. Oxidized low-density lipoprotein receptor 1 provides a route of entry for oxidized low-density lipoprotein into the endothelium. A human atherosclerotic lesion also expresses lipoprotein-associated phospholipase A 2 . Short conclusion Atherosclerotic plaques are the battlefield between an unbalanced immune response and lipid accumulation in the intima of arteries. Most of the biomarkers associated with atherosclerosis are indicators of inflammatory response and will also be used for medical purposes.
Targeting B cells and plasma cells in autoimmune diseases: from established treatments to novel therapeutic approaches

Ana Merino‐Vico,Giulia Frazzei,Jan Piet van Hamburg,Sander W. Tas

DOI: https://doi.org/10.1002/eji.202149675

2022-11-02

European Journal of Immunology

Abstract:Autoimmune diseases are characterized by the recognition of self‐antigens by the immune system, which leads to inflammation and tissue damage. B cells are directly and indirectly involved in the pathophysiology of autoimmunity, both via antigen‐presentation to T cells and production of proinflammatory cytokines and/or autoantibodies. Consequently, B lineage cells have been identified as therapeutic targets in autoimmune diseases. B cell depleting strategies have proven beneficial in the treatment of rheumatoid arthritis (RA), systemic lupus erythematous (SLE), ANCA‐associated vasculitis (AAV), multiple sclerosis (MS), and a wide range of other immune‐mediated inflammatory diseases (IMIDs). However, not all patients respond to treatment or may not reach (drug‐free) remission. Moreover, B cell depleting therapies do not always target all B cell subsets, such as short‐lived and long‐lived plasma cells. These cells play an active role in autoimmunity and in certain diseases their depletion would be beneficial to achieve disease remission. In the current review article we provide an overview of novel strategies to target B lineage cells in autoimmune diseases, with the focus on rheumatic diseases. Both advanced therapies that have recently become available and more experimental treatments that may reach the clinic in the near future are discussed. This article is protected by copyright. All rights reserved

immunology
The immune system in atherosclerosis

Göran K Hansson,Andreas Hermansson

DOI: https://doi.org/10.1038/ni.2001

IF: 30.5

2011-02-15

Nature Immunology

Abstract:Cardiovascular disease, a leading cause of mortality worldwide, is caused mainly by atherosclerosis, a chronic inflammatory disease of blood vessels. Lesions of atherosclerosis contain macrophages, T cells and other cells of the immune response, together with cholesterol that infiltrates from the blood. Targeted deletion of genes encoding costimulatory factors and proinflammatory cytokines results in less disease in mouse models, whereas interference with regulatory immunity accelerates it. Innate as well as adaptive immune responses have been identified in atherosclerosis, with components of cholesterol-carrying low-density lipoprotein triggering inflammation, T cell activation and antibody production during the course of disease. Studies are now under way to develop new therapies based on these concepts of the involvement of the immune system in atherosclerosis.

immunology
Immunobiology of Atherosclerosis: A Complex Net of Interactions

Beatriz Herrero-Fernandez,Raquel Gomez-Bris,Beatriz Somovilla-Crespo,Jose Maria Gonzalez-Granado,Herrero-Fernandez,Gomez-Bris,Somovilla-Crespo,Gonzalez-Granado

DOI: https://doi.org/10.3390/ijms20215293

IF: 5.6

2019-10-24

International Journal of Molecular Sciences

Abstract:Cardiovascular disease is the leading cause of mortality worldwide, and atherosclerosis the principal factor underlying cardiovascular events. Atherosclerosis is a chronic inflammatory disease characterized by endothelial dysfunction, intimal lipid deposition, smooth muscle cell proliferation, cell apoptosis and necrosis, and local and systemic inflammation, involving key contributions to from innate and adaptive immunity. The balance between proatherogenic inflammatory and atheroprotective anti-inflammatory responses is modulated by a complex network of interactions among vascular components and immune cells, including monocytes, macrophages, dendritic cells, and T, B, and foam cells; these interactions modulate the further progression and stability of the atherosclerotic lesion. In this review, we take a global perspective on existing knowledge about the pathogenesis of immune responses in the atherosclerotic microenvironment and the interplay between the major innate and adaptive immune factors in atherosclerosis. Studies such as this are the basis for the development of new therapies against atherosclerosis

biochemistry & molecular biology,chemistry, multidisciplinary
Atherosclerosis: Insights into Vascular Pathobiology and Outlook to Novel Treatments

Marc P. Wolf,Patrick Hunziker

DOI: https://doi.org/10.1007/s12265-020-09961-y

2020-02-19

Journal of Cardiovascular Translational Research

Abstract:The pathobiology of atherosclerosis and its current and potential future treatments are summarized, with a spotlight on three central cell types involved: (i) endothelial cells (ECs), (ii) macrophages, and (iii) vascular smooth muscle cells (VSMCs). (i) EC behaviour is regulated by the central transcription factors YAP/TAZ in reaction to biomechanical forces, such as hemodynamic shear stress. (ii) VSMC transdifferentiation (phenotype switching) to a macrophage-like phenotype contributes to the majority of cells positive for common cell surface macrophage markers in atherosclerotic plaques. (iii) Intra-plaque macrophages originate in a significant number from vascular resident macrophages. They can be activated via pattern recognition receptors on cell membrane (e.g. toll-like receptors) and inside cells (e.g. inflammasomes), requiring priming by neutrophil extracellular traps (NETs). ECs and macrophages can also be characterized by single-cell RNA sequencing. Adaptive immunity plays an important role in the inflammatory process. Future therapeutic options include vaccination, TRAF-STOPs, senolysis, or CD47 blockade.

cardiac & cardiovascular systems,medicine, research & experimental
Similarity of the three-dimensional structures of actin and the ATPase fragment of a 70-kDa heat shock cognate protein.

K. Flaherty,D. Mckay,W. Kabsch,K. Holmes

DOI: https://doi.org/10.1073/PNAS.88.11.5041

1991-06-01

Abstract:Although there is very little sequence identity between the two proteins, the structures of rabbit skeletal muscle actin (375-amino acid residues) and the 44-kDa ATPase fragment of the bovine 70-kDa heat shock cognate protein (HSC70; 386 residues) are very similar. The alpha-carbon positions of 241 pairs of amino acid residues that are structurally equivalent within the two proteins can be superimposed with a root-mean-square difference in distance of 2.3 A; of these, 39 residues are identical, and 56 are conservative substitutions. In addition, the conformations of ADP are very similar in both proteins. A local sequence "fingerprint," which may be diagnostic of the adenine nucleotide beta-phosphate-binding pocket, has been derived. The fingerprint identifies members of the glycerol kinase family as candidates likely to have a similar structure in their nucleotide-binding domains. The structural differences between the two molecules mainly occur in loop regions of actin known to be involved in interactions with other monomers in the actin filament or in the binding of myosin; the corresponding regions in heat shock proteins may have functions that are as yet undetermined. Placing the Ca2+ ATP of actin on the ATPase fragment structure suggests Asp-206 (corresponding to His-161 of actin) as a candidate proton acceptor for the ATPase reaction.

Serum immune biomarkers in irritable bowel syndrome.

B Cells in Atherosclerosis: Mechanisms and Potential Clinical Applications

Functional Role of B Cells in Atherosclerosis

Beyond Macrophages and T Cells: B Cells and Immunoglobulins Determine the Fate of the Atherosclerotic Plaque

Atherosclerosis antigens as targets for immunotherapy

B cells and atherosclerosis: A HIV perspective

Antibodies in action: the role of humoral immunity in the fight against atherosclerosis

T Cells in Atherosclerosis: Key Players in the Pathogenesis of Vascular Disease

Atherosclerosis: Beyond the lipid storage hypothesis. The role of autoimmunity

Tipping the Scale: Atheroprotective IgM-Producing B Cells in Atherosclerosis

ApoB-Specific CD4+ T Cells in Mouse and Human Atherosclerosis

Targeting immune cell recruitment in atherosclerosis

Abstract 21: B-1b Cells Secrete Atheroprotective IgM and Attenuate Atherosclerosis

Single-cell profiling of CD11c+ B cells in atherosclerosis

Inhibitory effects of apple polyphenol on induced histamine release from RBL-2H3 cells and rat mast cells.

The cellular biology of atherosclerosis with atherosclerotic lesion classification and biomarkers

Targeting B cells and plasma cells in autoimmune diseases: from established treatments to novel therapeutic approaches

The immune system in atherosclerosis

Immunobiology of Atherosclerosis: A Complex Net of Interactions

Atherosclerosis: Insights into Vascular Pathobiology and Outlook to Novel Treatments

Similarity of the three-dimensional structures of actin and the ATPase fragment of a 70-kDa heat shock cognate protein.